Tags

Type your tag names separated by a space and hit enter

Tegaserod for constipation-predominant irritable bowel syndrome.
Pharmacotherapy. 2007 Feb; 27(2):267-77.P

Abstract

Tegaserod, a selective and partial agonist at the 5-hydroxytryptamine (5-HT [serotonin]) receptor subtype 4 (5-HT4), is the only United States Food and Drug Administration-approved drug for the treatment of constipation-predominant irritable bowel syndrome (IBS) in women. The drug's stimulation of 5-HT4 receptors on intestinal enterocytes increases peristaltic activity and fluid secretion into the gut lumen, facilitating stool passage. In addition, affinity of tegaserod for 5-HT4 receptors modulates visceral sensitivity, which helps alleviate abdominal pain associated with constipation-predominant IBS. The drug's pharmacokinetic and pharmacodynamic parameters do not differ significantly with age or sex. Tegaserod safely and effectively relieves overall gastrointestinal symptoms and abdominal discomfort and normalizes bowel habits in patients with constipation-predominant IBS. It is associated with few drug interactions. In clinical studies, tegaserod was well tolerated, and its adverse-effect profile was similar to that of placebo. Severe diarrhea, as well as abdominal pain, flatulence, headache, and nausea, were the most commonly reported events. Patients who experience severe diarrhea should discontinue the drug. With the data available, tegaserod remains an option for patients with constipation-predominant IBS.

Authors+Show Affiliations

Department of Pharmacy Practice, Wayne State University, Detroit, Michigan 48236-2172, USA. pkale@wayne.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17253916

Citation

Kale-Pradhan, Pramodini B., and Sheila M. Wilhelm. "Tegaserod for Constipation-predominant Irritable Bowel Syndrome." Pharmacotherapy, vol. 27, no. 2, 2007, pp. 267-77.
Kale-Pradhan PB, Wilhelm SM. Tegaserod for constipation-predominant irritable bowel syndrome. Pharmacotherapy. 2007;27(2):267-77.
Kale-Pradhan, P. B., & Wilhelm, S. M. (2007). Tegaserod for constipation-predominant irritable bowel syndrome. Pharmacotherapy, 27(2), 267-77.
Kale-Pradhan PB, Wilhelm SM. Tegaserod for Constipation-predominant Irritable Bowel Syndrome. Pharmacotherapy. 2007;27(2):267-77. PubMed PMID: 17253916.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tegaserod for constipation-predominant irritable bowel syndrome. AU - Kale-Pradhan,Pramodini B, AU - Wilhelm,Sheila M, PY - 2007/1/27/pubmed PY - 2007/4/6/medline PY - 2007/1/27/entrez SP - 267 EP - 77 JF - Pharmacotherapy JO - Pharmacotherapy VL - 27 IS - 2 N2 - Tegaserod, a selective and partial agonist at the 5-hydroxytryptamine (5-HT [serotonin]) receptor subtype 4 (5-HT4), is the only United States Food and Drug Administration-approved drug for the treatment of constipation-predominant irritable bowel syndrome (IBS) in women. The drug's stimulation of 5-HT4 receptors on intestinal enterocytes increases peristaltic activity and fluid secretion into the gut lumen, facilitating stool passage. In addition, affinity of tegaserod for 5-HT4 receptors modulates visceral sensitivity, which helps alleviate abdominal pain associated with constipation-predominant IBS. The drug's pharmacokinetic and pharmacodynamic parameters do not differ significantly with age or sex. Tegaserod safely and effectively relieves overall gastrointestinal symptoms and abdominal discomfort and normalizes bowel habits in patients with constipation-predominant IBS. It is associated with few drug interactions. In clinical studies, tegaserod was well tolerated, and its adverse-effect profile was similar to that of placebo. Severe diarrhea, as well as abdominal pain, flatulence, headache, and nausea, were the most commonly reported events. Patients who experience severe diarrhea should discontinue the drug. With the data available, tegaserod remains an option for patients with constipation-predominant IBS. SN - 0277-0008 UR - https://www.unboundmedicine.com/medline/citation/17253916/Tegaserod_for_constipation_predominant_irritable_bowel_syndrome_ L2 - https://doi.org/10.1592/phco.27.2.267 DB - PRIME DP - Unbound Medicine ER -